Description
Anti-CD6 Antibody, Highly Galactosylated (BioBet-GA-159ZP) is a humanized IgG1, κ antibody against CD6 which contains with a high level of galactosylation.
Antibody Indication
Psoriasis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD6 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
CD6 (CD6 Molecule) is a Protein Coding gene.
Diseases associated with CD6 include Bronchus Cancer and Inflammatory Bowel Disease 16.
Among its related pathways are Cell adhesion molecules (CAMs).
Gene Ontology (GO) annotations related to this gene include scavenger receptor activity.
An important paralog of this gene is LOXL4.
Alternative Names
Itolizumab; Alzumab; 1116433-11-4; T1h; Alzumab; CD6; CD6 molecule; CD6 antigen; T-cell differentiation antigen CD6; Tp120; T12; TP120; FLJ44171;
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Its related pathways are Cell adhesion molecules (CAMs).
Related Pathways
Cell adhesion molecules, through the interaction with ALCAM/CD166, mediate cell-cell contact and regulate T cell response (PubMed:15048703, PubMed:15294938, PubMed:16352806, PubMed:16914752, PubMed:24945728, PubMed:24584089 ). Participate in the signal cascade triggered by the activation of TCR/CD3 complex (PubMed: 24584089). As a costimulatory molecule; promote T cell activation and proliferation (PubMed:15294938, PubMed:16352806, PubMed:16914752). Contribute to the formation and maturation of immune synapses (PubMed:15294938, PubMed:16352806). As a calcium-dependent model receptor, it binds and aggregates Gram-positive and Gram-negative bacteria. Combines lipopolysaccharide (LPS) of gram-negative bacteria and lipoteichoic acid of gram-positive bacteria (PubMed: 17601777). LPS binding leads to the activation of the signaling cascade and downstream MAP kinase (PubMed: 17601777). Mediates activation of inflammatory response and secretion of pro-inflammatory cytokines in response to LPS (PubMed:17601777).
Function
Developmental Biology antibody; Immune System antibody
Field of research
After T-cell activation, becomes hyperphosphorylated on Ser and Thr residues and phosphorylated on Tyr residues. Glycosylated.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-GA-159ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD6. Itolizumab (INN, trade name Alzumab) is a 'first in class' humanized IgG1 monoclonal antibody. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation. A double blind, placebo controlled, phase III treat -Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo.
Antibody Indication
Psoriasis
